Compound Centella asiatica formula alleviates Schistosoma japonicum-induced liver fibrosis in mice by inhibiting the inflammation-fibrosis cascade via regulating the TLR4/MyD88 pathway.
10.12122/j.issn.1673-4254.2025.06.20
- Author:
Liping GUAN
1
;
Yan YAN
1
;
Xinyi LU
1
;
Zhifeng LI
1
;
Hui GAO
2
;
Dong CAO
1
;
Chenxi HOU
1
;
Jingyu ZENG
1
;
Xinyi LI
1
;
Yang ZHAO
2
;
Junjie WANG
2
;
Huilong FANG
1
Author Information
1. School of Basic Medical Sciences, Xiangnan University, Chenzhou 423000, China.
2. School of Pharmacy, Xiangnan University, Chenzhou 423000, China.
- Publication Type:Journal Article
- Keywords:
Schistosoma japonicum-induced hepatic fibrosis;
compound Centella asiatica formula;
experimental validation;
molecular docking;
network pharmacology
- MeSH:
Animals;
Toll-Like Receptor 4/metabolism*;
Mice;
Myeloid Differentiation Factor 88/metabolism*;
Schistosoma japonicum;
Liver Cirrhosis/parasitology*;
Schistosomiasis japonica;
Signal Transduction;
Molecular Docking Simulation;
Inflammation;
Centella/chemistry*;
Drugs, Chinese Herbal/pharmacology*;
Tumor Necrosis Factor-alpha/metabolism*
- From:
Journal of Southern Medical University
2025;45(6):1307-1316
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To explore the therapeutic mechanism of compound Centella asiatica formula (CCA) for alleviating Schistosoma japonicum (Sj)-induced liver fibrosis in mice.
METHODS:The active components and targets of CCA were identified using the TCMSP database with cross-analysis of Sj-related liver fibrosis targets. A "drug-component-target-pathway-disease" network was constructed using Cytoscape 3.9.1. Functional enrichment analysis (GO/KEGG) was performed using DAVID. Molecular docking study was carried out to validate interactions between the core targets and the key compounds. For experimental validation of the results, 36 mice were divided into control group, Sj-infected model group, and CCA-treated groups. In the latter two groups, liver fibrosis was induced via abdominal infection with Sj cercariae for 8 weeks, followed by 8 weeks of daily treatment with CCA decoction or saline. Hepatic pathology of the mice was assessedwith HE and Masson staining, and hepatic expressions of collagen-I and collagen-III were detected using immunohistochemistry; serum IL-6 and TNF-α levels were determined with ELISA. Hepatic expressions of TLR4 and MyD88 proteins were analyzed with Western blotting.
RESULTS:We identified a total of 107 bioactive CCA components and 791 targets, including 37 intersection targets linked to Sj-induced fibrosis. The core targets included TNF, TP53, JUN, MMP9, and CXCL8, involving the IL-17 signaling, lipid metabolism, TLR4/MyD88 axis, and cancer pathways. Molecular docking study confirmed strong binding affinity between quercetin (a primary CCA component) and TNF/TP53/JUN/MMP9. In Sj-infected mouse models, CCA treatment significantly attenuated hepatic inflammatory cell infiltration, reduced collagen-I and collagen-III deposition, improved tissue architecture, reduced serum IL-6 and TNF-α levels, and downregulated TLR4 and MyD88 expressions in the liver.
CONCLUSIONS:CCA mitigates Sj-induced liver fibrosis by targeting TNF, TP53, JUN, and MMP9 to modulate the TLR4/MyD88 pathway, thereby suppressing pro-inflammatory cytokine release, inhibiting hepatic stellate cell activation, reducing collagen deposition, and preventing granuloma formation in the liver.
